TissueLink Medical, formerly known as Salient Surgical Technologies, Inc., has been pioneering global medical technology since 1999. The company develops and markets advanced energy devices for use in surgical procedures, with a focus on improving patient outcomes. Their proprietary Transcollation™ Technology has been utilized in over 200,000 surgical procedures to date, demonstrating its widespread acceptance in the medical community.
The company's products find application in various medical specialties including orthopedic reconstruction, spine and surgical oncology, showcasing their versatile utility in enhancing surgical techniques. Their latest funding round amounted to $15.00M from RiverVest, Medtronic, Arnerich Massena & Associates on 07 January 2010, indicating sustained investor confidence in the company's potential.
TissueLink's commitment to advancing medical technology positions it as a promising prospect for investors seeking opportunities in the biotechnology, health care, and marketing industries. With a strong track record and innovative solutions, the company holds promise for continued growth and positive impact on patient care worldwide.
